Third-quarter net sales came in at $1.29 billion compared with the $1.24 billion provided in a company-compiled consensus.
Sign up here.
Galderma highlighted strong growth particularly in its Nemluvio dermatology portfolio and said it is focusing further on the U.S. market to support this momentum.
Galderma raises full-year outlook after sales beat, commits to US manufacturing
